Diana Marszalek 10 Dec 2020 // 1:00AM GMT
NEW YORK — Kathryn Metcalfe has stepped down from her role as Bristol Myers Squibb's corporate affairs head, less than a year after joining the drug maker from CVS Health, where she lead communications.
"Kathryn Metcalfe, who served as executive vice president of corporate affairs since January 2020, has departed from Bristol Myers Squibb. We have an interim structure in place and a talented, diverse team who will continue to engage stakeholders around our company strategy, the performance of our business, the promise of our pipeline, and our patient-focused mission," the company said in a statement.
Metcalfe joined BMS following the retirement of John Elicker, who led corporate affairs and investor relations. Before joining BMS, she held chief communications officer roles at CVS Health, Aetna and Deloitte.
Metcalfe's November departure comes amidst other changes in BMS' communications function.
Ben Trounson has stepped down from his role leading Tata Consultancy Services' global communications to join BMS as head of international corporate affairs.
Trounson assumed his role as VP of international corporate affairs with the pharmaceutical giant earlier this month after seven years with TCS. He replaces Wioletta Niznik, who has been named VP of corporate reputation.
At BMS, Trounson is responsible for driving the corporate, product and pipeline communications strategies and campaigns across global regions outside of the US.
"He leads a diverse team, focused on aligning and empowering the implementation of international and market specific initiatives that build upon its commercial and local community relationships, strengthen the company’s brand positioning and support local business priorities," BMS said in a statement.
For the last year, Trounson has served as chief communications officer and head of North American marketing for TCS. He joined the company in 2003 to lead North American corporate communications after holding senior leadership roles at agencies including H+K Strategies and Ketchum.
BMS reported $26.1bn in revenue for 2019, during which it acquired Celgene, which makes cancer and immunology drugs. Eliquis, Opdivo, and Orencia were BMS's top selling drugs that year.